Limited Toxicity and Impressive Outcomes of Upfront Flag-Based Induction in Newly Diagnosed Acute Myeloid Leukemia: An Indian Scenario

被引：0
|
作者：
Soni, Mayank [1 ]
Rainchwar, Sujay [2 ]
Shaikh, Mohd Rizwan [3 ]
Singh, Reema [1 ]
Sheth, Vipul [1 ]
Panda, Tribikram [1 ]
Halder, Rohan [1 ]
Palatty, Roy J. [1 ]
Agrawal, Narendra [1 ]
Senapati, Jayastu [4 ]
Bhurani, Dinesh [1 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, New Delhi, India
[2] Sashwat Hematoonco Associates, Rajkot, Gujarat, India
[3] KEM, Mumbai, Maharashtra, India
[4] MD Anderson Canc Ctr, Dallas, TX USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
AML; acute myeloid leukemia; FLAG; anthracycline-free; induction; sepsis;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-696
引用
收藏
页码：S331 / S331
页数：1
相关论文
共 50 条
  • [31] Early-onset venous thromboembolisms in newly diagnosed non-promyelocytic acute myeloid leukemia patients undergoing intensive induction chemotherapy
    Koschade, Sebastian E.
    Stratmann, Jan A.
    Steffen, Bjoern
    Shaid, Shabnam
    Finkelmeier, Fabian
    Serve, Hubert
    Miesbach, Wolfgang
    Brandts, Christian H.
    Ballo, Olivier
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (04) : 426 - 434
  • [32] Clinical Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia Receiving Treatment in a Safety-Net Hospital System
    Lu, Jason
    Bhakta, Preeya
    Hwang, Hyunsoo
    Lachowiez, Curtis
    Apostolidou, Effrosyni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (05) : 349 - 356
  • [33] Differences in Outcomes of Newly Diagnosed Acute Myeloid Leukemia for Adolescent/Young Adult and Younger Patients A Report from the Children's Oncology Group
    Canner, Jason
    Alonzo, Todd A.
    Franklin, Janet
    Freyer, David R.
    Gamis, Alan
    Gerbing, Robert B.
    Lange, Beverly J.
    Meshinchi, Soheil
    Woods, William G.
    Perentesis, John
    Horan, John
    CANCER, 2013, 119 (23) : 4162 - 4169
  • [34] Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study
    Mustafa Ali, Moaath K.
    Corley, Elizabeth M.
    Alharthy, Hanan
    Kline, Kathryn A. F.
    Law, Jennie Y.
    Lee, Seung Tae
    Niyongere, Sandrine
    Duong, Vu H.
    Emadi, Ashkan
    Baer, Maria R.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse
    Irish, William
    Ryan, Michael
    Gache, Larry
    Gunnarsson, Candace
    Bell, Timothy
    Shapiro, Mark
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (03) : 519 - 527
  • [36] Efficacy and safety of cladribine addition to induction treatment of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis
    Pan, Qianying
    Li, Juan
    HEMATOLOGY, 2021, 26 (01) : 577 - 587
  • [37] Outpatient-Based Low-intensity Induction With Sorafenib in FLT3-ITD-Mutated Newly Diagnosed Acute Myeloid Leukemia (AML)
    Baskarane, Hemavathi
    Sahoo, Ranjit Kumar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S292 - S293
  • [38] Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy
    Choi, Michelle
    Song, Jinlin
    Bui, Cat N.
    Ma, Esprit
    Chai, Xinglei
    Yin, Lei
    Betts, Keith A.
    Kapustyan, Tatyana
    Montez, Melissa
    LeBlanc, Thomas William
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (09) : 980 - 988
  • [39] Outcomes in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML) Who Achieved Remission with CPX-351 Versus 7+3 Induction: Exploratory Analysis of a Phase 3 Study
    Faderl, Stefan
    Cortes, Jorge E.
    Ritchie, Ellen K.
    Ryan, Robert J.
    Chiarella, Michael
    Schiller, Gary J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S206 - S207
  • [40] Real World Data on Clinical Outcomes of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated With Hypomethylating Agents (HMA) Plus Shorter Duration of Venetoclax (VEN) at a General Hospital
    Khan, Hina
    Yohannan, Binoy
    Cervoni-Curet, Frances
    Rios, Adan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S262 - S262
12345